These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 8962227)

  • 1. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
    Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients.
    Millis JM; Bruce DS; Newell KA; Piper JB; Woodle ES; Seaman DS; Baker AL; Hart J; Dasgupta K; Thistlethwaite JR
    Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 6. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 8. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract]   [Full Text] [Related]  

  • 9. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.
    Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O
    Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients.
    Kliem V; Schaumann D; Ehlerding G; Eberhard OK; Lufft V; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1997 Nov; 29(7):2955-7. PubMed ID: 9365627
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection.
    Herget S; Heemann U; Friedrich J; Kribben A; Wagner K; Philipp T
    Clin Nephrol; 1996 May; 45(5):352-4. PubMed ID: 8738671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fate of renal allografts treated with OKT3 for steroid-resistant rejection.
    Veronese FV; Gonçalves LF; Vilarinho LL; Macedo VS; Manfro RC
    Transplant Proc; 1999 Nov; 31(7):3016-8. PubMed ID: 10578371
    [No Abstract]   [Full Text] [Related]  

  • 13. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients.
    Kliem V; Petersen R; Ehlerding G; Schaumann D; Eisenberger U; Koch KM; Pichlmayr R; Brunkhorst R
    Transplant Proc; 1998 Jun; 30(4):1251-3. PubMed ID: 9636509
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy.
    Scott-Douglas N; Zimmerman D; Klassen J
    Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
    Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study.
    Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D
    Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
    Niese D
    Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.